Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetes

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Gomez-Muñoz, Laia
• dc.contributor.author Perna-Barrull, David
• dc.contributor.author Caroz-Armayones, Josep M.
• dc.contributor.author Murillo, Marta
• dc.contributor.author Rodriguez-Fernandez, Silvia
• dc.contributor.author Valls, Aina
• dc.contributor.author Vazquez, Federico
• dc.contributor.author Pérez, Jacobo
• dc.contributor.author Corripio, Raquel
• dc.contributor.author Castaño, Luis
• dc.contributor.author Bel, Joan
• dc.contributor.author Vives-Pi, Marta
• dc.date.accessioned 2025-02-25T07:07:10Z
• dc.date.available 2025-02-25T07:07:10Z
• dc.date.issued 2022
• dc.description.abstract The partial remission (PR) phase, a period experienced by most patients with type 1 diabetes (T1D) soon after diagnosis, is characterized by low insulin requirements and improved glycemic control. Given the great potential of this phase as a therapeutic window for immunotherapies because of its association with immunoregulatory mechanisms and β-cell protection, our objective was to find peripheral immunological biomarkers for its better characterization, monitoring, and prediction. The longitudinal follow-up of 17 pediatric patients with new-onset T1D over one year revealed that, during the PR phase, remitter patients show increased percentages of effector memory (EM) T lymphocytes, terminally differentiated EM T lymphocytes, and neutrophils in comparison to non-remitter patients. On the contrary, remitter patients showed lower percentages of naïve T lymphocytes, regulatory T cells (TREG), and dendritic cells (DCs). After a year of follow-up, these patients also presented increased levels of regulatory B cells and transitional T1 B lymphocytes. On the other hand, although none of the analyzed cytokines (IL-2, IL-6, TGF-β1, IL-17A, and IL-10) could distinguish or predict remission, IL-17A was increased at T1D diagnosis in comparison to control subjects, and remitter patients tended to maintain lower levels of this cytokine than non-remitters. Therefore, these potential monitoring immunological biomarkers of PR support that this stage is governed by both metabolic and immunological factors and suggest immunoregulatory attempts during this phase. Furthermore, since the percentage of TREG, monocytes, and DCs, and the total daily insulin dose at diagnosis were found to be predictors of the PR phase, we next created an index-based predictive model comprising those immune cell percentages that could potentially predict remission at T1D onset. Although our preliminary study needs further validation, these candidate biomarkers could be useful for the immunological characterization of the PR phase, the stratification of patients with better disease prognosis, and a more personalized therapeutic management.en
• dc.format.mimetype application/pdf
• dc.identifier.citation Gomez-Muñoz L, Perna-Barrull D, Caroz-Armayones JM, Murillo M, Rodriguez-Fernandez S, Valls A, et al. Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetes. Front Immunol. 2022 Feb 23;13:825426. DOI: 10.3389/fimmu.2022.825426
• dc.identifier.doi http://dx.doi.org/10.3389/fimmu.2022.825426
• dc.identifier.issn 1664-3224
• dc.identifier.uri http://hdl.handle.net/10230/69693
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Frontiers in Immunology. 2022 Feb 23;13:825426
• dc.rights © 2022 Gomez-Muñoz, Perna-Barrull, Caroz-Armayones, Murillo, Rodriguez-Fernandez, Valls, Vazquez, Perez, Corripio, Castaño, Bel and Vives-Pi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Type 1 diabetes (T1D)en
• dc.subject.keyword Partial remission phaseen
• dc.subject.keyword Honeymoonen
• dc.subject.keyword Biomarkersen
• dc.subject.keyword Pediatricsen
• dc.subject.keyword Prediction modelen
• dc.subject.keyword Immune cell subpopulationsen
• dc.subject.keyword Autoimmunityen
• dc.title Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetesen
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion